While immune checkpoint inhibitors(ICIs)are adopted as standard therapy for advanced non-small cell lung cancer(NSCLC),genetic determinants of response heterogeneity remain elusive[1].As most hematopoietic lineages un...While immune checkpoint inhibitors(ICIs)are adopted as standard therapy for advanced non-small cell lung cancer(NSCLC),genetic determinants of response heterogeneity remain elusive[1].As most hematopoietic lineages undergo dynamic changes during tumor pathogenesis and immunotherapy[2],elucidating how germline variants modulate their transcriptomes is critical.Expression quantitative trait loci(eQTL)analysis,especially integrated with single-cell RNA sequencing(scRNA-seq),enables gene regulation mapping at single-cell resolution[3,4].Detailed methodologies are described in the Supplementary Materials.展开更多
基金the Korean Research Foundation(NRF-2021R1A2C3014067,NRF-RS-2023-00207857 to Murim Choi,NRF-2020R1A2C3006535,NRF-RS-2025-00519956 to Se-Hoon Lee)the Korea Health Technology R&D Project through the Korea Health Industry Development Institute(HR20C0025 to Se-Hoon Lee)Future Medicine 20*30 Project of the Samsung Medical Center(SMX1230041 to Se-Hoon Lee).
文摘While immune checkpoint inhibitors(ICIs)are adopted as standard therapy for advanced non-small cell lung cancer(NSCLC),genetic determinants of response heterogeneity remain elusive[1].As most hematopoietic lineages undergo dynamic changes during tumor pathogenesis and immunotherapy[2],elucidating how germline variants modulate their transcriptomes is critical.Expression quantitative trait loci(eQTL)analysis,especially integrated with single-cell RNA sequencing(scRNA-seq),enables gene regulation mapping at single-cell resolution[3,4].Detailed methodologies are described in the Supplementary Materials.
